Bevacizumab for corneal neovascularization

Ophthalmology. 2009 Mar;116(3):592-3; author reply 593-4. doi: 10.1016/j.ophtha.2008.10.011.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Administration, Topical
  • Adult
  • Aged
  • Angiogenesis Inhibitors / administration & dosage*
  • Angiogenesis Inhibitors / adverse effects
  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Corneal Neovascularization / drug therapy*
  • Corneal Neovascularization / physiopathology
  • Epithelium, Corneal / drug effects
  • Epithelium, Corneal / pathology
  • Female
  • Humans
  • Intraocular Pressure / drug effects
  • Male
  • Middle Aged
  • Prognosis
  • Tonometry, Ocular
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Visual Acuity / drug effects

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Vascular Endothelial Growth Factor A
  • Bevacizumab